Status:
UNKNOWN
Black Garlic Nutraceuticals and Blood Pressure Control
Lead Sponsor:
Universitat de Lleida
Collaborating Sponsors:
Pharmactive, S.L.
Conditions:
Hypertension
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Black garlic contains a series of allyl-sulfur compounds with the ability to modulate nitric oxide synthetase, angiotensin-converting enzyme system, and endothelial activation, which together could he...
Eligibility Criteria
Inclusion
- \- Clinical hypertension, medically treated with no more than 2 drugs
Exclusion
- Body mass index above 35 kg/m2
- Fasting blood cholesterol levels below 115 mg/dL
- Fasting blood glucose levels above 126 mg/dL
- Taking anyone of the Angiotensin-converting enzyme inhibitors
- Anemia (hemoglobin below 13 g/dL in men and below 12 g/dL in women)
- Vitamin or nutraceutical intake in the last 30 days before the study enrollment
- Chronic gastrointestinal diseases
- Pregnancy and breastfeeding
- Garlic allergy
- Participation in another study 30 days before the study enrollment
Key Trial Info
Start Date :
May 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04915053
Start Date
May 15 2021
End Date
June 30 2022
Last Update
June 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Arnau de Vilanova
Lleida, Spain, 25198